Literature DB >> 1269488

Ketamine hydrochloride and its effect on a chronic cobalt epileptic cortical focus.

G R DeVore, J K McQueen, D M Woodbury.   

Abstract

The effects of anesthetic and nonanesthetic doses of ketamine hydrochloride were studied in male adult rats in which a primary and a projected epileptic focus were induced with implantation of cobalt in the right or left frontal cortex. Electrical activity was recorded from the frontal, parietal, and occipital cortices. Nonanesthetic doses of ketamine were associated with activation or enhancement of primary and projected focal electrical activity, as well as turning behavior toward the side of the cobalt focus. Anesthetic doses of ketamine also enhanced or activated the primary and projected foci. These animals demonstrated turning behavior toward the side of the cobalt focus prior to and following the cataleptoid state. During catalepsy, forelimb twitching and oscillating movements of the vibrissae occurred. The activation of primary and projected foci by ketamine at anesthetic and nonanesthetic doses supports the clinical findings that ketamine is epileptogenic in certain patients with a seizure disorder.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1269488     DOI: 10.1111/j.1528-1157.1976.tb03389.x

Source DB:  PubMed          Journal:  Epilepsia        ISSN: 0013-9580            Impact factor:   5.864


  2 in total

Review 1.  Ketamine in the Past, Present, and Future: Mechanisms, Metabolites, and Toxicity.

Authors:  Eric S Schwenk; Basant Pradhan; Rohit Nalamasu; Lucas Stolle; Irving W Wainer; Michael Cirullo; Alexander Olsen; Joseph V Pergolizzi; Marc C Torjman; Eugene R Viscusi
Journal:  Curr Pain Headache Rep       Date:  2021-07-16

2.  Ketamine and its combinations with valproate and carbamazepine are ineffective against convulsions induced by atropine treatment and food intake in fasted mice.

Authors:  Neriman Gözüaçık; Aslı Zengin Türkmen; Asiye Nurten; Nurhan Enginar
Journal:  Iran J Basic Med Sci       Date:  2019-03       Impact factor: 2.699

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.